Reduced Paraoxonase 1 Activity as a Marker for Severe Coronary Artery Disease

Table 2

Clinical and laboratory characteristics of the participants in the study.

Parameters	Non-CAD patients	All CAD patients	P	Mild CAD	Moderate CAD	Severe CAD
	(𝑛=31)	(𝑛=118)		(Score ≤ 10, 𝑛=27)	(10 < score ≤ 40, 𝑛=43)	(Score > 40, 𝑛=48)
Gensini score	2.08±1.72	37.03±30.89	<0.001**	6.67±2.03	20.17±7.03^##	69.20±21.95^##▵
Age (yrs)	59.3±8.3	61.6±9.2	0.205	61.4±10.7	61.7±9.4	61.6±8.3
Sex (male/female)	22/9	83/35	0.946	15/12	31/12	37/11
Smoking	12 (38.7%)	36 (30.5%)	0.597	7 (25.9%)	10 (23.3%)	19 (39.6%)
Diabetes (𝑛 (%))	3 (9.7%)	42 (35.6%)	0.005**	8 (29.6%)	13 (30.2%)*	21 (43.8%)**
Hypertention (𝑛 (%))	12 (38.7%)	79 (66.9%)	0.004**	20 (74.1%)**	25 (58.1%)	34 (70.8%)**
Triglycerides (mmol/L)	1.14 (0.95~1.61)	1.50 (1.14~2.35)	0.009**	2.32 (1.23~3.85)**	1.46 (1.20~2.07)	1.53 (1.04~2.23)
TC (mmol/L)	4.16±0.80	4.42±1.29	0.285	4.65±1.36	4.33±1.35	4.38±1.22
LDL-C (mmol/L)	2.63±0.70	2.70±1.00	0.711	2.53±0.94	2.76±1.11	2.74±0.94
HDL-C (mmol/L)	1.15±0.28	0.95±0.22	<0.001**	0.99±0.25^∗	0.92±0.23^∗∗	0.94±0.18^∗∗
HDL-C/LDL-C	0.47±0.18	0.39±0.13	0.004**	0.39±0.11	0.38±0.13	0.37±0.13
ApoAI (g/L)	1.22±0.20	1.09±0.24	0.007**	1.21±0.30	1.08±0.25^∗#	1.03±0.17^∗∗##
ApoB100 (g/L)	0.87±0.22	0.90±0.27	0.597	0.86±0.22	0.91±0.33	0.91±0.25
ApoAI/ApoB100	1.51±0.41	1.27±0.38	0.002**	1.40±0.37	1.22±0.34	1.21±0.37
Lipoprotein(a) (mg/dL)	84.8 (40.9~176.4)	78.6 (39.5~173.1)	0.912	66.7 (21.9~118.7)	87.5 (39.7~167.0)	94.9 (41.3~268.4)
PON1 activity (U/mL)	506.4±118.8	368.2±120.0	<0.001**	404.3±117.6^∗∗	403.8±113.6^∗∗	316.0±109.5^∗∗##▵
hs-CRP (mg/L)	1.60 (0.31~2.56)	2.40 (0.99~6.17)	0.003**	1.58 (0.80~4.07)	1.53 (0.81~4.46)	4.30 (2.00~9.02)^**##∆

Data for continuous variables as mean ± SD or median (25th and 75th percentiles); data presented as numbers (percentages) of participants.
^∗𝑃<0.05, ^∗∗𝑃<0.01, compared with non-CAD group; ^#𝑃<0.05, ^##𝑃<0.01, compared with mild stenosis; ^▵𝑃<0.01, compared with moderate stenosis.